1349 logo

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd SHSC:1349 Stock Report

Last Price

HK$2.49

Market Cap

HK$7.0b

7D

-8.8%

1Y

2.0%

Updated

19 Dec, 2024

Data

Company Financials

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd.

SHSC:1349 Stock Report

Market Cap: HK$7.0b

1349 Stock Overview

Engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. More details

1349 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Risk Analysis

Earnings have declined by 9.2% per year over past 5 years

Volatile share price over the past 3 months compared to the Hong Kong market

Large one-off items impacting financial results


My Notes

Capture your thoughts, links and company narrative

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Competitors

Beijing Tong Ren Tang Chinese Medicine

SEHK:3613

HK$7.1b

Luye Pharma Group

SEHK:2186

HK$8.1b

Tong Ren Tang Technologies

SEHK:1666

HK$6.4b

China Shineway Pharmaceutical Group

SEHK:2877

HK$7.2b

Price History & Performance

Summary of share price highs, lows and changes for Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd
Historical stock prices
Current Share PriceHK$2.49
52 Week HighHK$4.42
52 Week LowHK$1.70
Beta0.23
1 Month Change-7.43%
3 Month Change39.11%
1 Year Change2.05%
3 Year Change-35.32%
5 Year Changen/a
Change since IPO-46.79%

Recent News & Updates

Recent updates

Shareholder Returns

1349HK PharmaceuticalsHK Market
7D-8.8%-3.3%-2.2%
1Y2.0%-2.4%18.3%

Return vs Industry: 1349 exceeded the Hong Kong Pharmaceuticals industry which returned -4% over the past year.

Return vs Market: 1349 underperformed the Hong Kong Market which returned 19.2% over the past year.

Price Volatility

Is 1349's price volatile compared to industry and market?
1349 volatility
1349 Average Weekly Movement16.8%
Pharmaceuticals Industry Average Movement6.4%
Market Average Movement8.9%
10% most volatile stocks in HK Market18.7%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 1349's share price has been volatile over the past 3 months compared to the Hong Kong market.

Volatility Over Time: 1349's weekly volatility has increased from 9% to 17% over the past year.

About the Company

FoundedEmployeesCEOWebsite
1996913Da Jun Zhaowww.fd-zj.com/DesktopModules/HT/chinese/home/Index.aspx

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd., together with its subsidiaries, engages in the research, development, manufacture, and sale of bio-pharmaceutical products primarily in China. It offers genetic engineering platform drugs, including CD30-DM1 antibody-drug conjugate (ADC), which is in Phase I clinical trials for tumors; Trop2-SN38 ADC that is in Phase I clinical trials for triple negative, breast, bladder, gastric, and other tumors; Trop2-BB05 ADC that is in pre-clinical studies for lung cancer and triple negative breast cancer; DLL3-BB05 ADC that is in pre-clinical trials for tumors; and HER2 ADC that has carried out phase I clinical study for metastatic breast and gastric cancers. The company also provides photodynamic technical platform drugs, such as hemoporfin for port wine stain, which is in Phase IV clinical trial; and aminolevulinic acid, which is in Phase II clinical trials for cervical diseases infected by HPV and acne, as well as completed pre-clinical study for brain gliomas.

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Fundamentals Summary

How do Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd's earnings and revenue compare to its market cap?
1349 fundamental statistics
Market capHK$6.97b
Earnings (TTM)HK$112.03m
Revenue (TTM)HK$736.52m

23.0x

P/E Ratio

3.5x

P/S Ratio

Is 1349 overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1349 income statement (TTM)
RevenueCN¥691.62m
Cost of RevenueCN¥64.16m
Gross ProfitCN¥627.46m
Other ExpensesCN¥522.25m
EarningsCN¥105.20m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.10
Gross Margin90.72%
Net Profit Margin15.21%
Debt/Equity Ratio0%

How did 1349 perform over the long term?

See historical performance and comparison

Dividends

1.7%

Current Dividend Yield

94%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/19 02:47
End of Day Share Price 2024/12/19 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack HuDeutsche Bank
Feng Qiang SunGuotai Junan International Holdings Limited
Xiang JunIndustrial Securities Co. Ltd.